VisionGate Revenue and Competitors

Phoenix, AZ USA



Total Funding



Estimated Revenue & Valuation

  • VisionGate's estimated annual revenue is currently $2.2M per year.(i)
  • VisionGate's estimated revenue per employee is $77,500
  • VisionGate's total funding is $58.2M.

Employee Data

  • VisionGate has 29 Employees.(i)
  • VisionGate grew their employee count by 21% last year.

VisionGate's People

Founder, Chairman & CEOReveal Email/Phone
CTOReveal Email/Phone
VP Advanced Prod. Dev.Reveal Email/Phone
Senior Manufacturing EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is VisionGate?

VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia. The foundation for our diagnostics capability is the proprietary Cell-CTᅢᄁ¬ダᅡᄁ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies. Our lead diagnostic product is the LuCEDᅢツᅡᆴ lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. LuCED lung test utilizes the Cell-CT platform and is in development for the early detection of lung cancer, bronchial dysplasia and the assessment of indeterminate pulmonary nodules (IPN). The LuCED test includes CellGazerᅢᄁ¬ダᅡᄁ application, an imaging software tool under development to facilitate cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform. Our lead investigative pharmaceutical product iloprost, an oral prostacyclin analog, has progressed through an NCI-sponsored Phase 2 clinical trial. Iloprost is a potential first-in-class lung cancer prevention drug in clinical development to treat former smokers for the reduction of moderate to severe bronchial dysplasia as measured by the LuCEDᅢツᅡᆴ lung test. The LuCED test is being developed as a companion diagnostic to iloprost. The LuCED test and iloprost portfolio provides VisionGate the potential unique ability to both identify and treat patients with pre-cancerous bronchial dysplasia. Follow us on Linked In for updates and visit



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding